-DOCSTART- -X- O
INTRODUCTION -X- _ O
: -X- _ O
Sarcoidosis -X- _ O
is -X- _ O
an -X- _ O
incurable -X- _ O
, -X- _ O
chronic -X- _ O
granulomatous -X- _ O
disease -X- _ O
primarily -X- _ O
involving -X- _ O
the -X- _ O
lungs -X- _ O
and -X- _ O
lymph -X- _ O
nodes -X- _ O
of -X- _ O
unknown -X- _ O
aetiology -X- _ O
, -X- _ O
treated -X- _ O
with -X- _ O
non-specific -X- _ O
anti-inflammatory -X- _ O
/ -X- _ O
immunosuppressive -X- _ O
drugs. -X- _ O
Persistently -X- _ O
symptomatic -X- _ O
patients -X- _ O
worsen -X- _ O
with -X- _ O
a -X- _ O
disabling -X- _ O
, -X- _ O
potentially -X- _ O
fatal -X- _ O
clinical -X- _ O
course. -X- _ O
To -X- _ O
determine -X- _ O
a -X- _ O
possible -X- _ O
infectious -X- _ O
cause -X- _ O
, -X- _ O
we -X- _ O
correlated -X- _ O
in -X- _ O
a -X- _ O
case-control -X- _ O
study -X- _ O
the -X- _ O
clinical -X- _ O
information -X- _ O
with -X- _ O
the -X- _ O
presence -X- _ B-Intervention
of -X- _ I-Intervention
bacterial -X- _ I-Intervention
DNA -X- _ I-Intervention
in -X- _ I-Intervention
sarcoidosis -X- _ I-Intervention
mediastinal -X- _ I-Intervention
lymph -X- _ I-Intervention
nodes -X- _ I-Intervention
compared -X- _ O
with -X- _ O
control -X- _ B-Comparision
lymph -X- _ I-Comparision
nodes -X- _ I-Comparision
resected -X- _ I-Comparision
during -X- _ I-Comparision
cancer -X- _ I-Comparision
surgery -X- _ I-Comparision
. -X- _ O

METHODS -X- _ O
: -X- _ O
We -X- _ O
retrospectively -X- _ O
studied -X- _ O
formalin-fixed -X- _ B-Intervention
, -X- _ I-Intervention
paraffin-embedded -X- _ I-Intervention
, -X- _ I-Intervention
mediastinal -X- _ I-Intervention
lymph -X- _ I-Intervention
nodes -X- _ I-Intervention
from -X- _ I-Intervention
30 -X- _ I-Intervention
patients -X- _ I-Intervention
with -X- _ I-Intervention
sarcoidosis -X- _ I-Intervention
and -X- _ O
30 -X- _ B-Comparision
control -X- _ I-Comparision
patients -X- _ I-Comparision
with -X- _ I-Comparision
lung -X- _ I-Comparision
cancer. -X- _ I-Comparision
Nucleic -X- _ O
acids -X- _ O
were -X- _ O
extracted -X- _ O
from -X- _ O
nodes -X- _ O
, -X- _ O
evaluated -X- _ O
by -X- _ O
ribosomal -X- _ O
RNA -X- _ O
PCR -X- _ O
for -X- _ O
bacterial -X- _ O
16S -X- _ O
ribosomal -X- _ O
DNA -X- _ O
and -X- _ O
the -X- _ O
results -X- _ O
were -X- _ O
sequenced -X- _ O
and -X- _ O
compared -X- _ O
with -X- _ O
a -X- _ O
bacterial -X- _ O
sequence -X- _ O
library. -X- _ O
Clinical -X- _ O
information -X- _ O
was -X- _ O
correlated -X- _ O
. -X- _ O

RESULTS -X- _ O
: -X- _ O
11 -X- _ B-Outcome
/ -X- _ I-Outcome
30 -X- _ I-Outcome
( -X- _ I-Outcome
36.7 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
lymph -X- _ I-Outcome
nodes -X- _ I-Outcome
from -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
sarcoidosis -X- _ I-Outcome
had -X- _ I-Outcome
detectable -X- _ I-Outcome
bacterial -X- _ I-Outcome
DNA -X- _ I-Outcome
, -X- _ I-Outcome
significantly -X- _ I-Outcome
more -X- _ I-Outcome
than -X- _ I-Outcome
control -X- _ I-Outcome
patient -X- _ I-Outcome
lymph -X- _ I-Outcome
nodes -X- _ I-Outcome
( -X- _ I-Outcome
2 -X- _ I-Outcome
/ -X- _ I-Outcome
30 -X- _ I-Outcome
, -X- _ I-Outcome
6.7 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
p=0.00516. -X- _ I-Outcome
At -X- _ I-Outcome
presentation -X- _ I-Outcome
, -X- _ I-Outcome
19 -X- _ I-Outcome
/ -X- _ I-Outcome
30 -X- _ I-Outcome
( -X- _ I-Outcome
63.3 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
sarcoidosis -X- _ I-Outcome
were -X- _ I-Outcome
symptomatic -X- _ I-Outcome
including -X- _ I-Outcome
all -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
detectable -X- _ I-Outcome
bacterial -X- _ I-Outcome
DNA. -X- _ I-Outcome
Radiographically -X- _ I-Outcome
, -X- _ I-Outcome
there -X- _ I-Outcome
were -X- _ I-Outcome
18 -X- _ I-Outcome
stage -X- _ I-Outcome
I -X- _ I-Outcome
and -X- _ I-Outcome
12 -X- _ I-Outcome
stage -X- _ I-Outcome
II -X- _ I-Outcome
patients. -X- _ I-Outcome
All -X- _ I-Outcome
stage -X- _ I-Outcome
II -X- _ I-Outcome
patients -X- _ I-Outcome
were -X- _ I-Outcome
symptomatic -X- _ I-Outcome
and -X- _ I-Outcome
75 -X- _ I-Outcome
% -X- _ I-Outcome
had -X- _ I-Outcome
PCR-detectable -X- _ I-Outcome
bacteria. -X- _ I-Outcome
After -X- _ I-Outcome
a -X- _ I-Outcome
mean -X- _ I-Outcome
follow-up -X- _ I-Outcome
of -X- _ I-Outcome
52.8Â±32.8 -X- _ I-Outcome
months -X- _ I-Outcome
, -X- _ I-Outcome
all -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
PCR-detectable -X- _ I-Outcome
bacteria -X- _ I-Outcome
in -X- _ I-Outcome
this -X- _ I-Outcome
series -X- _ I-Outcome
were -X- _ I-Outcome
persistently -X- _ I-Outcome
symptomatic -X- _ I-Outcome
requiring -X- _ I-Outcome
treatment. -X- _ I-Outcome
DISCUSSION -X- _ O
: -X- _ O
36.6 -X- _ B-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
sarcoidosis -X- _ I-Outcome
had -X- _ I-Outcome
detectable -X- _ I-Outcome
bacterial -X- _ I-Outcome
DNA -X- _ I-Outcome
on -X- _ I-Outcome
presentation -X- _ I-Outcome
, -X- _ I-Outcome
all -X- _ I-Outcome
of -X- _ I-Outcome
these -X- _ I-Outcome
patients -X- _ I-Outcome
were -X- _ I-Outcome
quite -X- _ I-Outcome
symptomatic -X- _ I-Outcome
and -X- _ I-Outcome
most -X- _ I-Outcome
were -X- _ I-Outcome
radiographically -X- _ I-Outcome
advanced -X- _ I-Outcome
stage -X- _ I-Outcome
II. -X- _ I-Outcome
These -X- _ O
findings -X- _ O
suggest -X- _ O
that -X- _ O
bacterial -X- _ O
DNA-positive -X- _ O
, -X- _ O
symptomatic -X- _ B-Patient
patients -X- _ I-Patient
have -X- _ O
more -X- _ O
aggressive -X- _ O
sarcoidosis -X- _ O
that -X- _ O
persists -X- _ O
long -X- _ O
term -X- _ O
and -X- _ O
might -X- _ O
benefit -X- _ O
from -X- _ O
antimicrobial -X- _ O
treatment -X- _ O
directed -X- _ O
against -X- _ O
this -X- _ O
presumed -X- _ O
chronic -X- _ O
granulomatous -X- _ O
infection -X- _ O
. -X- _ O

